REGN241108C950000
- 0.32
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
Regeneron Pharma Is Maintained at Outperform by Oppenheimer
Regeneron Pharmaceuticals Analyst Ratings
Today's Analyst Rating | Meta Platforms Price Target Raised to $655 by Loop Capital, Citigroup Price Target Raised to $107 by Oppenheimer
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,000
Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment
Express News | Regeneron - Dupixent (Dupilumab) Approved in European Union as First and Only Medicine for Young Children With Eosinophilic Esophagitis
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,126
Regeneron Pharmaceuticals Insider Sold Shares Worth $844,610, According to a Recent SEC Filing
Tuesday Market Closed Up, with Presidency in Sight | Wall Street Today
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
We Want YOU to Submit Questions for Election Night
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,110
Monday Market Moves Sideways, Election and FOMC in Sight | Wall Street Today
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Monday Market Mixed Before Crazy, Pivotal Week | Live Stock
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)